Yuewei Medical Secures Nearly RMB 100 Million Series A++ Financing to Accelerate Innovation and Domestic Substitution in Critical Coronary Artery Disease Diagnosis and Treatment Devices

VCBeat exclusively learned that Yellwin, which focuses on the research and development of innovative medical devices for cardiac surgery,Yellwin (hereinafter referred to as "Yellwin")Announced the completion byBeijing Medical and Health Industry Investment FundExclusive investment of tens of millions of yuan in the A++ round of financing.

This round of financing will be mainly used in two directions: one is to deepen the innovation of full-process instruments for coronary heart disease diagnosis and treatment, as well as the research and development of new products like the pulsatile left ventricular assist system; the other is to accelerate the market promotion of already approved products such as cardiac stabilizers. Through the empowerment of this round of financing, Yellwin will comprehensively strengthen its R&D innovation and market penetration capabilities in the cardiovascular field, continuously consolidating its leading position in technology.

Yellwin was founded in September 2021 by the cardiac surgery team from Anzhen Hospital and senior executives from the medical device industry. Headquartered in Beijing, the company has assembled a multidisciplinary team with expertise in clinical medicine, medical device hardware, and AI algorithms. Drawing on the founding team's extensive experience in cardiac surgery, the company identifies clinical needs and develops innovative medical devices, including a new-generation heart stabilizer, vascular anastomosis quality control system, and coronary artery disease scoring system—all of which are either first-of-their-kind in China or fill market gaps. The company holds over 50 patents globally and is recognized as a national high-tech enterprise and a specialized, refined, distinctive, and innovative enterprise.

With the deepening of the centralized procurement policy and the full rollout of DRG payment reform, coupled with the rapid enhancement of surgical capabilities at regional medical centers in China, the volume of cardiac surgeries in China has been showing a high growth trend since 2021.The number of surgeries in fields such as coronary artery surgery and extracorporeal circulation has seen significant growth for many consecutive years.

According to incomplete statistics from the "White Paper on Cardiovascular Surgical Operations and Extracorporeal Circulation Data in China," the volume of cardiovascular surgeries in China increased by approximately 29.8% in 2023, with the number of extracorporeal circulation procedures rising by over 26%. Among the subfields, coronary artery bypass surgeries saw an increase of about 30%, leading the growth. However, this field has long been constrained by challenges such as the concentration of surgical resources and the low level of domestic production of medical devices, with foreign companies like Medtronic and Maquet dominating the market for a long time.

Originating from a deep insight into clinical pain points, the Yellwin team, based on years of frontline cardiothoracic surgical diagnosis and treatment experience, boldly innovated to address the pain points exposed by imported devices in China's clinical scenarios. They developedA new generation of high-end coronary surgical devices, including cardiac stabilizers, bridge vessel flow meters, new proximal anastomosis systems, and minimally invasive great saphenous vein harvesting systems, has achieved full-process coverage of instruments in the coronary surgery field.

In response to the trend of severe illness and complex surgeries among patients in China, the team simultaneously developedInnovative devices for preoperative assessment and critical surgical assistance, such as the intelligent SYNTAX scoring system, pulsatile left ventricular assist, and femoral arteriovenous cannulation,Provide a localized solution for Chinese cardiothoracic surgeons, covering preoperative evaluation to intraoperative support, offering a Chinese approach to address severe cardiac treatments in the era of aging.

Influenced by various factors, the medical device industry has entered a structural adjustment cycle in recent years. Yellwin, with its precise grasp of clinical needs, has established a dual-wheel development model of "clinical validation-driven innovation, and commercial transformation feeding back into R&D." The company adopts a strategy of "moderately forward-looking R&D + gradient commercial transformation," balancing both R&D and commercialization.Its core product, the heart stabilizer series, obtained certification just one year ago and has already covered nearly 80% of cardiac surgery centers in China.

To build a multi-level product ecosystem,Yellwin has also launched multiple products targeting research services and animal experiments.With the completion of this round of financing, the company will continue to accelerate the commercialization process and upgrade to become a comprehensive solution provider for cardiovascular surgery.

Dr. Wenyan Yu, Co-founder and CEO of YellwinExpressed: Thank you to the Beijing Medical and Health Industry Investment Fund for your trust and support in the Yellwin team. Entrepreneurship is challenging, and on one hand, we will continue to focus on commercialization efforts to achieve positive operating cash flow as soon as possible. On the other hand, we will remain true to our original aspiration, always remembering that we are a company serving doctors and patients, and product innovation will forever be our core competitiveness. Moreover, as an industry company mainly comprised of a doctor team, Yellwin not only understands the needs of clinical doctors in scientific research transformation but also has some knowledge of the medical device development process. We warmly welcome doctors who have scientific research transformation needs to reach out to us.

Professor Yang Yu, Chief Scientist of YellwinYellwin stated: "Originating from clinical practice, surpassing clinical practice, and returning to clinical practice" is the core concept of Yellwin's product development. To implement this concept, we have made product improvements targeting the shortcomings of existing devices, leading to the creation of multiple products such as the Yellwin heart stabilizer and proximal anastomosis system. On the other hand, we are accelerating progress in the field of domestic alternatives, developing China’s first domestically produced alternative devices like the vascular anastomosis quality control system and femoral artery-vein cannula. Additionally, to align with the trends towards minimally invasive and critical care procedures, we developed the world's first high-flow, pulsatile percutaneous left ventricular assist system without DSA assistance. In the future, we will also develop several disruptive innovative devices, such as a minimally invasive small vessel anastomosis system, to ensure that Yellwin becomes a company that can both stand firm and go far.

Beijing Medical and Health Industry Investment FundRepresentation: The company focuses on the research and development of innovative medical devices in the field of cardiac surgery. Based on unmet clinical needs in China and the team's extensive first-line clinical experience, it fully leverages the interdisciplinary advantages of combining medical and engineering expertise to develop life-support equipment and solutions covering the entire diagnosis and treatment process for major diseases such as coronary heart disease and heart failure. The product pipeline balances innovation in R&D with commercial viability, progressively addressing and filling various niche market gaps in China.